Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New adaptive software aims to keep aging minds connected and engaged

NCT ID NCT07485712

Knowledge-focused Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study is developing and testing an intelligent software system designed to provide cognitive and social support to older adults with mild cognitive impairment (MCI). The software adapts to each user's abilities and needs. Researchers will enroll 290 participants aged 62 and older with MCI to see how usable and helpful the system is over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intelligent Adaptive System (software)
What this could lead to
If successful, this could lead to a practical tool that helps older adults with mild cognitive impairment stay socially and mentally engaged at home.
What could go wrong
This is an early-stage development study focused on usability, not on proving health benefits. The software may not improve cognition or delay decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 62+ years of age * Able to read English at the 6th grade level * Have 20/60 vision with or without correction. * Clinical diagnosis of mild cognitive impairment (MCI) * Subjective cognitive complaints * Evidence by clinical evaluation * Clinical Dementia Rating Global scale of 0.5-2.0 * Probable MCI * Montreal Cognitive Assessment (MoCA) score of 18-26 * No major Instrumental activities of daily living (IADL) impairments * Geriatric Depression Scale of 4 or Below * No diagnosis of dementia Exclusion Criteria: * Blind or have visual impairments that limit their ability to view the technology. * Deaf or have hearing impairments that limit their ability to answer telephone queries. * Have a life-limiting/terminal illness * Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand * Cognitive impairment (MOCA ≤ 25)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Florida State University

    Tallahassee, Florida, 32306, United States

  • University of Illinois Urbana-Champaign

    Champaign, Illinois, 61820, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.